Guggenheim Securities analysts raised their price target for Absci Corporation and maintained a "Buy" rating on June 15 [1, 2].
This adjustment follows early clinical success for the company's hair-loss treatment, signaling potential growth for the biotechnology firm's pipeline. The move reflects growing investor confidence in the company's ability to translate AI-driven antibody design into viable medical therapies.
Guggenheim analysts increased the price target to $15 from $10 [1]. Other reports noted the target at $10 [3], but multiple sources confirm the upward revision to $15 [1, 2]. The optimistic outlook is tied to positive interim Phase 1 safety data for ABS-201, an antibody designed to treat hair loss [2, 4].
Market reaction to the clinical results was immediate. Absci shares surged 24% following the release of the early clinical data [4]. Despite this volatility, the company previously reported a closing share price of $3.01 on the day of a separate market report [3].
To capitalize on this momentum, Absci announced a $100 million stock offering [5]. This capital raise comes as the company prepares for the next stage of its clinical trials. Analysts are now looking toward the second half of 2026, when the company expects to release proof-of-concept data for the ABS-201 therapy [2].
Absci is listed on the NASDAQ and operates as a U.S. biotechnology company [1, 6]. The firm focuses on using generative AI to accelerate the creation of antibodies, a process that traditionally takes years of trial and error in a laboratory setting.
“Guggenheim analysts increased the price target to $15 from $10”
The price target increase and the $100 million stock offering suggest that Absci is moving from a theoretical AI platform to a clinical-stage company. By targeting hair loss—a high-demand consumer health market—Absci is attempting to prove its generative AI capabilities with a visible, tangible outcome before pursuing more complex diseases. The upcoming proof-of-concept data in late 2026 will be the primary catalyst for the stock's long-term valuation.
